Price hike coming for Australia Post stamps
The price of Australia Post stamps will be hiked next month following approval from the country's consumer watchdog.
A stamp for a basic small letter will increase from $1.50 to $1.70, which the Australian Competition and Consumer Commission says is still less than in comparable countries.
Across the board, prices are going up a little over 13 per cent.
'We are especially mindful of the impact price changes can have on vulnerable Australians and so our decision paper recommends that Australia Post increases the number of concession stamps per customer, which is currently capped at 50 per year,' ACCC commissioner Anna Brakey said.
'We understand that these price increases will mean extra costs for consumers,' she said.
However, Australia Post loses money running the national letter service, Ms Brakey said.
Following the ACCC's approval, announced Monday, Communications Minister Anika Wells can still reject the price increase.
NewsWire has contacted the Minister's office for comment.
Fewer and fewer Australians send and receive letters.
In submissions made to the ACCC, Australia Post says each household receives only two letters each week.
But the ACCC wants Australia Post to work out ways to make letters cheaper for businesses that are required to send them.
'As there are many businesses in Australia that still rely on sending letters, it is crucial that Australia Post has a transparent dialogue with these customers so they are aware of potential pricing changes well ahead of time,' Ms Brakey said.
'While Australia Post has been working constructively with the ACCC on these recommendations, in most instances, we expect full implementation to be reached, so that we can conduct rigorous cost-based assessments going forward,' Ms Brakey said.
The average price of a single postage stamp in OECD countries is $1.93.
From next month, large letters up to 125g will increase from $3.00 to $3.40.
Ordinary large letters between 125g and 250g are going up from $4.50 to $5.10.
Concession stamps will remain $3 for five stamps, and seasonal greeting cards are staying at 65c.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Illuccix Approved in U.S. for Patient Selection for Pre-Taxane RLT
MELBOURNE, Australia and INDIANAPOLIS, June 23, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, 'Telix', 'the Company') today announces that the United States (U.S.) Food and Drug Administration (FDA) has approved a label expansion for Illuccix® (kit for the preparation of gallium Ga-68 gozetotide, for injection) to include patient selection for radioligand therapy (RLT) in the pre-taxane setting. The update applies to Illuccix's third indication, for selection of patients who are indicated for PSMA1-directed therapy as described in the Prescribing Information of the therapeutic products. The label expansion follows the FDA's approval of an expanded label for Pluvicto®2 (lutetium Lu177 vipivotide tetraxetan) for use in metastatic castration-resistant prostate cancer (mCRPC) patients after treatment with androgen receptor pathway inhibitor (ARPI) therapy and before chemotherapy3. With RLT now approved for use earlier in the patient journey, the clinical utilization of Illuccix® is expected to increase by at least 20,000 scans annually4. Scott T. Tagawa, MD, a genitourinary (GU) oncologist in New York said, 'It is pleasing to see the ability to use gallium-68 PSMA-PET for patient selection expanded. This empowers clinicians to make more informed, personalized decisions earlier in the disease course and access life-prolonging targeted radionuclide therapy for more patients with prostate cancer.' Kevin Richardson, Chief Executive Officer, Precision Medicine, Telix, said, 'We're pleased that the U.S. label for Illuccix has been expanded to support patient selection for RLT in the pre-taxane setting, aligning with the evolving treatment landscape. PSMA-PET imaging has become a standard of care in the detection and management of prostate cancer. With this update, patients can now benefit from the high diagnostic accuracy of Illuccix to identify those most likely to respond to PSMA-targeted therapy, even earlier in their treatment journey.' INDICATIONS AND USAGE Illuccix, after radiolabeling with Ga 68, is for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer: With suspected metastasis who are candidates for initial definitive therapy With suspected recurrence based on elevated serum prostate-specific antigen (PSA) level For selection of patients who are indicated for PSMA-directed therapy as described in the Prescribing Information of the therapeutic products IMPORTANT SAFETY INFORMATIONWARNINGS AND PRECAUTIONS Risk for MisinterpretationImage interpretation errors can occur with Illuccix PET. A negative image does not rule out the presence of prostate cancer, and a positive image does not confirm the presence of prostate cancer. Gallium Ga 68 gozetotide uptake is not specific for prostate cancer and may occur with other types of cancer as well as non-malignant processes such as Paget's disease, fibrous dysplasia, and osteophytosis. Clinical correlation, which may include histopathological evaluation of the suspected prostate cancer site, is recommended. Imaging Prior to Initial Definitive or Suspected Recurrence TherapyThe performance of Illuccix for imaging of biochemically recurrent prostate cancer seems to be affected by serum PSA levels and by site of disease. The performance of Illuccix for imaging of metastatic pelvic lymph nodes prior to initial definitive therapy seems to be affected by Gleason score. Radiation RisksGallium Ga 68 gozetotide contributes to a patient's overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk for cancer. Ensure safe handling to minimize radiation exposure to the patient and healthcare providers. Advise patients to hydrate before and after administration and to void frequently after administration. ADVERSE REACTIONSThe safety of gallium Ga 68 gozetotide was evaluated in 960 patients in the PSMA-PreRP and PSMA-BCR studies, each receiving one dose of gallium Ga 68 gozetotide. The average injected activity was 188.7 ± 40.7 MBq (5.1 ± 1.1 mCi). The most commonly reported adverse reactions were nausea, diarrhea, and dizziness, occurring at a rate of <1%.In the VISION study, 1003 patients received one dose of gallium Ga 68 gozetotide intravenously with the amount of radioactivity 167.1 ± 23.1 MBq (4.52 ± 0.62 mCi). Adverse reactions occurring at ≥0.5% in patients with metastatic prostate cancer who received gallium Ga 68 gozetotide injection in the clinical study were fatigue (1.2%), nausea (0.8%), constipation (0.5%), and vomiting (0.5%). Adverse reactions occurring at a rate of < 0.5% in the VISION study were diarrhea, dry mouth, injection site reactions, including injection site hematoma and injection site warmth and chills. DRUG INTERACTIONSAndrogen deprivation therapy and other therapies targeting the androgen pathwayAndrogen deprivation therapy (ADT) and other therapies targeting the androgen pathway, such as androgen receptor antagonists, can result in changes in uptake of gallium Ga 68 gozetotide in prostate cancer. The effect of these therapies on performance of gallium Ga 68 gozetotide PET has not been established. Please note that this information is not see the Full Prescribing Information . You are encouraged to report suspected adverse reactions of prescription drugs to the FDA. Visit MedWatch at or call 1-800-FDA-1088. You may also report adverse reactions to Telix by calling 1-844-455-8638 or emailing: pharmacovigilance@ Dr. Tagawa has served as a paid consultant to Telix and his institution has received research funding. Telix Investor Relations Ms. Kyahn WilliamsonTelix Pharmaceuticals LimitedSVP Investor Relations and Corporate CommunicationsEmail: Telix Media Relations (U.S.) Eliza Schleifstein ES Media Relations Email: eliza@ Phone: 917-763-8106 About Telix Pharmaceuticals Limited Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX). Illuccix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection), Telix's first generation PSMA-PET imaging agent, is approved and commercially available in multiple countries globally. Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection) has been approved by the U.S. FDA5. Visit for further information about Telix, including details of the latest share price, ASX and SEC filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook. Legal Notices You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website. The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement. This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as 'may', 'expect', 'intend', 'plan', 'estimate', 'anticipate', 'believe', 'outlook', 'forecast' and 'guidance', or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix's preclinical and clinical trials, and Telix's research and development programs; Telix's ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix's product candidates, manufacturing activities and product marketing activities; Telix's sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix's product candidates, if or when they have been approved; Telix's ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix's business; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. ©2025 Telix Pharmaceuticals Limited. Telix Pharmaceuticals®, Telix Group company, and Telix product names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved. Trademark registration status may vary from country to country. _________________________1 Prostate-specific membrane antigen2 Pluvicto is a registered trademark of Novartis AG and/or its affiliates.3 28 March 2025, FDA Statement: for patients who have been treated with ARPI therapy and are considered appropriate to delay taxane-based chemotherapy.4 Based on licensed indication for Pluvicto in mCRPC patients who have been treated with androgen receptor (AR) pathway inhibition.5 Telix ASX disclosure 21 March 2025.
Yahoo
an hour ago
- Yahoo
Shift4 to acquire Australia's Smartpay for NZ$296.4m
Integrated payments company Shift4 has agreed to acquire Australian payments company Smartpay for NZ$296.4m ($180m). The agreed acquisition price of NZ$1.20 per share represents a 46.5% premium over Smartpay's 90 trading day volume weighted average price (VWAP). Smartpay provides payment processing and point-of-sale solutions in Australia and New Zealand, supporting over 40,000 merchants through its distribution network. The deal, expected to close in the fourth quarter of 2025, is subject to regulatory approvals. Shift4 has previously applied this strategy in other regions, such as Germany, the UK, and Ireland, where it has sought to enhance its integrated payment experience through localised distribution, service, and support, as well as merchant-focused products and proprietary payment infrastructure. Shift4 CEO Taylor Lauber said: 'This acquisition follows the Shift4 playbook to a tee. It deepens our strategic presence in Australia and New Zealand, providing a significant opportunity to offer our full suite of software and payments solutions in the region. 'By combining our payment infrastructure with Smartpay's distribution capabilities, we're well positioned to go-to-market at scale in the region with our leading products and services such as SkyTab POS for restaurants, SkyTab Venue for stadiums and arenas, and our end-to-end payment solution for hotels and unified commerce merchants.' In February, Shift4 entered a $2.5bn deal to buy Swiss payments and technology firm Global Blue. With 40 years of experience, Global Blue operates at the intersection of travel and luxury retail across Europe, Asia, and South America. It is known for its two-sided network, connecting millions of international shoppers with merchants through its proprietary app. "Shift4 to acquire Australia's Smartpay for NZ$296.4m " was originally created and published by Electronic Payments International, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
3 hours ago
- Associated Press
Arkay Beverages Announces Strategic Alliance with Mexico's Largest Spirits Operator
MELBOURNE, Fla., June 23, 2025 /PRNewswire/ -- Arkay Beverages, the global pioneer in alcohol-free spirits, proudly announces that Licor Zone Mexico, the largest spirits producer and operator in Mexico, has signed a Memorandum of Understanding (MOU) to acquire a 10% equity stake in Arkay Beverages. This strategic partnership underscores Arkay's unwavering commitment to transparency, integrity, and sustainable growth—principles that several major global spirits conglomerates have failed to uphold. In response, Arkay has made the deliberate decision to distance itself from these entities and instead align with forward-thinking partners who share its values and long-term vision. With Arkay's primary production facility located in Mexico, this alliance with Licor Zone Mexico is a natural and strategic fit. It strengthens Arkay's operational foundation in the region while also providing the capital infusion needed to fuel global expansion. The terms of the agreement remain unchanged: 10% equity for $150 million, based on a $1.5 billion valuation. 'This is more than a financial transaction,' said Reynald Vito Grattagliano, founder of Arkay Beverages. 'It's a partnership built on mutual trust, strategic alignment, and a shared mission to redefine the future of zero-proof spirits. Why look halfway across the world for a Japanese partner, when the right one is already under our feet?' About Licor Zone Mexico Licor Zone is Mexico's largest spirits manufacturer, best known for its flagship brand Williamson 18, available in more than 18,267 liquor stores across the country. The company is a proud member of the Mexican Whisky Association and is based in Arandas, Jalisco—the heart of Mexico's tequila-producing region. [email protected] About Arkay Beverages Founded in 2011, Arkay Beverages is the world leader in alcohol-free spirits and zero-proof alternatives. With millions of bottles sold across five continents, Arkay continues to reshape the beverage industry by offering sophisticated, alcohol-free experiences for health-conscious and mindful consumers. Media Contact [email protected] View original content to download multimedia: SOURCE Arkay Beverages
